搜索筛选:
搜索耗时2.8008秒,为你在为你在102,285,761篇论文里面共找到 4 篇相符的论文内容
发布年度:
The role of the HGF/c-Met signaling pathway in crizotinib-induced apoptosis in lung cancer with c-Me
[期刊论文] 作者：Shaozhang Zhou,Zhixin Dong,Jinyi Lv,Aiping Zeng,Huilin Wang,Ruiling Ning,Xiangqun Song,,
来源：Oncology and Translational Medicine 年份：2017
Objective This study aimed to study the role of the HGF/c-Met signaling pathway in crizotinib-induced apoptosis of various lung adenocarcinoma cell lines and xe...
[期刊论文] 作者：Haiyan Peng,Wenhua Zhao,Cuiyun Su,Xiangqun Song,Aiping Zeng,Huilin Wang,Ruiling Ning,Shaozhang Zhou,,
来源：Oncology and Translational Medicine 年份：2015
Objective This study investigated the role of the STAT3/survivin signaling pathway in the EML4-ALK–positive lung adenocarcinoma cell line H2228 before and afte...
Dacomitinib versus Erlotinib in 2nd-/3rd-line NSCLC (ARCHER 1009 Global Phase Ⅲ trial):Outcomes in C
[会议论文] 作者：Tony Mok,Caicun Zhou,Ying Cheng,Xiangqun Song,Jin Wang,Gang Wu,Michael Boyer,Kenneth J.O'Byrne,Joseph,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
...
Dacomitinib versus Erlotinib in 2nd-/3rd-line NSCLC (ARCHER 1009 Global Phase Ⅲ trial):Outcomes in C
[会议论文] 作者：Caicun Zhou,Ying Cheng,Xiangqun Song,Jin Wang,Gang Wu,Michael Boyer,Kenneth J.O'Byrne,Joseph O'Connell,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
Objective: Dacomitinib (D) is an irreversible pan-HER kinase inhibitor.The ARCHER 1009 global phase Ⅲ study compared D and erlotinib (E) as treatment for locally advanced/metastatic non-small cell lun...
相关搜索：
